- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT04929041
Testování přidání radiační terapie k obvyklé léčbě (imunoterapie s chemoterapií nebo bez chemoterapie) u pacientů s nemalobuněčným karcinomem plic ve stádiu IV, kteří jsou PD-L1 negativní
Randomizovaná studie fáze II/III moderní systémové terapie založené na imunoterapii s nebo bez SBRT pro PD-L1-negativní, pokročilý nemalobuněčný karcinom plic
This phase II/III trial compares the addition of radiation therapy to the usual treatment (immunotherapy with or without chemotherapy) versus (vs.) usual treatment alone in treating patients with non-small cell lung cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic) whose tumor is also negative for a molecular marker called PD-L1. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill tumor cells and shrink tumors. Immunotherapy with monoclonal antibodies, such as nivolumab, ipilimumab may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The addition of radiation therapy to usual treatment may stop the cancer from growing and increase the life of patients with advanced non-small cell lung cancer who are PD-L1 negative.
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Detailní popis
PRIMARY OBJECTIVE:
I. To assess if radiation improves the progression free survival (PFS, phase II portion) and overall survival (OS, phase III portion) of advanced stage non-small cell lung cancer (NSCLC) patients with PD-L1 tumor proportion score (TPS) < 1% who receive immunotherapy with or without chemotherapy.
SECONDARY OBJECTIVES:
I. To estimate and compare the rates of >= grade 3-4 and all grade adverse events by Common Terminology Criteria for Adverse Events (CTCAE) version (v)5.0 between the arms.
II. To summarize and compare progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) between the arms.
III. To determine and compare the objective response rate (ORR) per RECIST between the arms (including at both irradiated and un-irradiated sites).
QUALITY OF LIFE (QOL) OBJECTIVE:
I. To assess the health-related QOL in both treatment arms.
CORRELATIVE SCIENCE OBJECTIVE:
I. To evaluate changes in the peripheral immune microenvironment between the arms.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM A: Patients receive nivolumab intravenously (IV) over 30 minutes on days 1 and 22 and ipilimumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 6 weeks for 24 months in the absence of disease progression or unacceptable toxicity or patients may receive standard of care systemic immunotherapy. Patients also undergo magnetic resonance imaging (MRI), computed tomography (CT), or positron emission tomography (PET) throughout the trial. Patients may undergo blood sample collection and tissue biopsy on study as well as echocardiography (ECHO) during screening.
Arm B: Patients receive nivolumab IV over 30 minutes on days 1 and 22 and ipilimumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 6 weeks for 24 months in the absence of disease progression or unacceptable toxicity or patients may receive standard of care systemic immunotherapy. Patients also undergo 3 fractions of radiation therapy every other day. Patients also undergo MRI, CT, or PET throughout the trial. Patients may undergo blood sample collection and tissue biopsy on study as well as ECHO during screening.
After completion of study treatment, patients are followed up every 3 months for 3 years and then every 6 months for years 4-5 following randomization until disease progression. Following disease progression patients are followed for survival every 6 months for up to 5 years following randomization.
Typ studie
Zápis (Odhadovaný)
Fáze
- Fáze 2
- Fáze 3
Kontakty a umístění
Studijní místa
-
-
Arizona
-
Phoenix, Arizona, Spojené státy, 85054
- Mayo Clinic Hospital in Arizona
-
-
Arkansas
-
Little Rock, Arkansas, Spojené státy, 72205
- University of Arkansas for Medical Sciences
-
-
California
-
Berkeley, California, Spojené státy, 94704
- Alta Bates Summit Medical Center-Herrick Campus
-
Duarte, California, Spojené státy, 91010
- City of Hope Comprehensive Cancer Center
-
Irvine, California, Spojené státy, 92618
- City of Hope at Irvine Lennar
-
Lancaster, California, Spojené státy, 93534
- City of Hope Antelope Valley
-
Marysville, California, Spojené státy, 95901
- Fremont - Rideout Cancer Center
-
Modesto, California, Spojené státy, 95355
- Memorial Medical Center
-
Napa, California, Spojené státy, 94558
- Providence Queen of The Valley
-
Sacramento, California, Spojené státy, 95817
- University of California Davis Comprehensive Cancer Center
-
South Pasadena, California, Spojené státy, 91030
- City of Hope South Pasadena
-
Truckee, California, Spojené státy, 96161
- Gene Upshaw Memorial Tahoe Forest Cancer Center
-
Upland, California, Spojené státy, 91786
- City of Hope Upland
-
-
Colorado
-
Colorado Springs, Colorado, Spojené státy, 80909
- UCHealth Memorial Hospital Central
-
Colorado Springs, Colorado, Spojené státy, 80920
- Memorial Hospital North
-
Fort Collins, Colorado, Spojené státy, 80524
- Poudre Valley Hospital
-
Fort Collins, Colorado, Spojené státy, 80528
- Cancer Care and Hematology-Fort Collins
-
Greeley, Colorado, Spojené státy, 80631
- UCHealth Greeley Hospital
-
Loveland, Colorado, Spojené státy, 80538
- Medical Center of the Rockies
-
-
Delaware
-
Millville, Delaware, Spojené státy, 19967
- Beebe South Coastal Health Campus
-
Newark, Delaware, Spojené státy, 19713
- Helen F Graham Cancer Center
-
Newark, Delaware, Spojené státy, 19713
- Medical Oncology Hematology Consultants PA
-
Rehoboth Beach, Delaware, Spojené státy, 19971
- Beebe Health Campus
-
-
District of Columbia
-
Washington D.C., District of Columbia, Spojené státy, 20010
- MedStar Washington Hospital Center
-
-
Florida
-
Aventura, Florida, Spojené státy, 33180
- UM Sylvester Comprehensive Cancer Center at Aventura
-
Clearwater, Florida, Spojené státy, 33756
- Morton Plant Hospital
-
Coral Gables, Florida, Spojené státy, 33146
- UM Sylvester Comprehensive Cancer Center at Coral Gables
-
Deerfield Beach, Florida, Spojené státy, 33442
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach
-
Miami, Florida, Spojené státy, 33136
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Miami, Florida, Spojené státy, 33176
- UM Sylvester Comprehensive Cancer Center at Kendall
-
Plantation, Florida, Spojené státy, 33324
- UM Sylvester Comprehensive Cancer Center at Plantation
-
Tampa, Florida, Spojené státy, 33607
- Saint Joseph's Hospital/Children's Hospital-Tampa
-
Winter Haven, Florida, Spojené státy, 33881
- Winter Haven Hospital
-
-
Georgia
-
Newnan, Georgia, Spojené státy, 30265
- CTCA at Southeastern Regional Medical Center
-
Savannah, Georgia, Spojené státy, 31405
- Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
-
-
Idaho
-
Boise, Idaho, Spojené státy, 83712
- Saint Luke's Cancer Institute - Boise
-
Fruitland, Idaho, Spojené státy, 83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian, Idaho, Spojené státy, 83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa, Idaho, Spojené státy, 83687
- Saint Luke's Cancer Institute - Nampa
-
Twin Falls, Idaho, Spojené státy, 83301
- Saint Luke's Cancer Institute - Twin Falls
-
-
Illinois
-
Chicago, Illinois, Spojené státy, 60611
- Northwestern University
-
Chicago, Illinois, Spojené státy, 60637
- University of Chicago Comprehensive Cancer Center
-
Chicago, Illinois, Spojené státy, 60612
- University of Illinois
-
Danville, Illinois, Spojené státy, 61832
- Carle at The Riverfront
-
DeKalb, Illinois, Spojené státy, 60115
- Northwestern Medicine Cancer Center Kishwaukee
-
Decatur, Illinois, Spojené státy, 62526
- Decatur Memorial Hospital
-
Effingham, Illinois, Spojené státy, 62401
- Crossroads Cancer Center
-
Effingham, Illinois, Spojené státy, 62401
- Carle Physician Group-Effingham
-
Geneva, Illinois, Spojené státy, 60134
- Northwestern Medicine Cancer Center Delnor
-
Glenview, Illinois, Spojené státy, 60026
- Northwestern Medicine Glenview Outpatient Center
-
Grayslake, Illinois, Spojené státy, 60030
- Northwestern Medicine Grayslake Outpatient Center
-
Harvey, Illinois, Spojené státy, 60426
- Ingalls Memorial Hospital
-
Lake Forest, Illinois, Spojené státy, 60045
- Northwestern Medicine Lake Forest Hospital
-
Mattoon, Illinois, Spojené státy, 61938
- Carle Physician Group-Mattoon/Charleston
-
New Lenox, Illinois, Spojené státy, 60451
- UC Comprehensive Cancer Center at Silver Cross
-
O'Fallon, Illinois, Spojené státy, 62269
- HSHS Saint Elizabeth's Hospital
-
Orland Park, Illinois, Spojené státy, 60462
- University of Chicago Medicine-Orland Park
-
Rockford, Illinois, Spojené státy, 61114
- UW Health Carbone Cancer Center Rockford
-
Springfield, Illinois, Spojené státy, 62702
- Southern Illinois University School of Medicine
-
Springfield, Illinois, Spojené státy, 62702
- Springfield Clinic
-
Springfield, Illinois, Spojené státy, 62781
- Springfield Memorial Hospital
-
Urbana, Illinois, Spojené státy, 61801
- Carle Cancer Center
-
Warrenville, Illinois, Spojené státy, 60555
- Northwestern Medicine Cancer Center Warrenville
-
-
Indiana
-
Crown Point, Indiana, Spojené státy, 46307
- UChicago Medicine Northwest Indiana
-
-
Iowa
-
Ames, Iowa, Spojené státy, 50010
- Mary Greeley Medical Center
-
Ames, Iowa, Spojené státy, 50010
- McFarland Clinic - Ames
-
Ankeny, Iowa, Spojené státy, 50023
- UI Health Care Mission Cancer and Blood - Ankeny Clinic
-
Clive, Iowa, Spojené státy, 50325
- Mercy Cancer Center-West Lakes
-
Clive, Iowa, Spojené státy, 50325
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Creston, Iowa, Spojené státy, 50801
- Greater Regional Medical Center
-
Des Moines, Iowa, Spojené státy, 50309
- Iowa Methodist Medical Center
-
Des Moines, Iowa, Spojené státy, 50314
- Mercy Medical Center - Des Moines
-
Des Moines, Iowa, Spojené státy, 50309
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Des Moines, Iowa, Spojené státy, 50314
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Waukee, Iowa, Spojené státy, 50263
- UI Health Care Mission Cancer and Blood - Waukee Clinic
-
West Des Moines, Iowa, Spojené státy, 50266
- Mercy Medical Center-West Lakes
-
West Des Moines, Iowa, Spojené státy, 50266
- The Iowa Clinic PC
-
-
Kentucky
-
Lexington, Kentucky, Spojené státy, 40536
- University of Kentucky/Markey Cancer Center
-
Lexington, Kentucky, Spojené státy, 40509
- CommonSpirit Saint Joseph Medical Center - East Lexington
-
-
Maine
-
Sanford, Maine, Spojené státy, 04073
- MaineHealth Cancer Care Center of York County
-
Scarborough, Maine, Spojené státy, 04074
- MaineHealth Maine Medical Center- Scarborough
-
South Portland, Maine, Spojené státy, 04106
- MaineHealth Cancer Care and IV Therapy - South Portland
-
-
Michigan
-
Ann Arbor, Michigan, Spojené státy, 48106
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Brighton, Michigan, Spojené státy, 48114
- Trinity Health IHA Medical Group Hematology Oncology - Brighton
-
Brighton, Michigan, Spojené státy, 48114
- Trinity Health Medical Center - Brighton
-
Canton, Michigan, Spojené státy, 48188
- Trinity Health IHA Medical Group Hematology Oncology - Canton
-
Canton, Michigan, Spojené státy, 48188
- Trinity Health Medical Center - Canton
-
Chelsea, Michigan, Spojené státy, 48118
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
-
Chelsea, Michigan, Spojené státy, 48118
- Chelsea Hospital
-
Flint, Michigan, Spojené státy, 48503
- Hurley Medical Center
-
Flint, Michigan, Spojené státy, 48503
- Genesys Hurley Cancer Institute
-
Kalamazoo, Michigan, Spojené státy, 49007
- West Michigan Cancer Center
-
Kalamazoo, Michigan, Spojené státy, 49007
- Bronson Methodist Hospital
-
Lansing, Michigan, Spojené státy, 48912
- University of Michigan Health - Sparrow Lansing
-
Livonia, Michigan, Spojené státy, 48154
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Pontiac, Michigan, Spojené státy, 48341
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
Pontiac, Michigan, Spojené státy, 48341
- Michigan Healthcare Professionals Pontiac
-
Saginaw, Michigan, Spojené státy, 48604
- Oncology Hematology Associates of Saginaw Valley PC
-
Saginaw, Michigan, Spojené státy, 48601
- MyMichigan Medical Center Saginaw
-
Tawas City, Michigan, Spojené státy, 48764
- MyMichigan Medical Center Tawas
-
West Branch, Michigan, Spojené státy, 48661
- Saint Mary's Oncology/Hematology Associates of West Branch
-
Ypsilanti, Michigan, Spojené státy, 48197
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
-
-
Minnesota
-
Duluth, Minnesota, Spojené státy, 55805
- Miller-Dwan Hospital
-
Minneapolis, Minnesota, Spojené státy, 55415
- Hennepin County Medical Center
-
Robbinsdale, Minnesota, Spojené státy, 55422
- North Memorial Medical Health Center
-
Saint Cloud, Minnesota, Spojené státy, 56303
- Coborn Cancer Center at Saint Cloud Hospital
-
Saint Paul, Minnesota, Spojené státy, 55101
- Regions Hospital
-
-
Missouri
-
Cape Girardeau, Missouri, Spojené státy, 63703
- Saint Francis Medical Center
-
Farmington, Missouri, Spojené státy, 63640
- Parkland Health Center - Farmington
-
Rolla, Missouri, Spojené státy, 65401
- Phelps Health Delbert Day Cancer Institute
-
Sainte Genevieve, Missouri, Spojené státy, 63670
- Sainte Genevieve County Memorial Hospital
-
Springfield, Missouri, Spojené státy, 65804
- Mercy Hospital Springfield
-
St Louis, Missouri, Spojené státy, 63131
- Missouri Baptist Medical Center
-
St Louis, Missouri, Spojené státy, 63141
- Mercy Hospital Saint Louis
-
St Louis, Missouri, Spojené státy, 63128
- Mercy Hospital South
-
Sullivan, Missouri, Spojené státy, 63080
- Missouri Baptist Sullivan Hospital
-
-
Montana
-
Bozeman, Montana, Spojené státy, 59715
- Bozeman Health Deaconess Hospital
-
-
New York
-
Buffalo, New York, Spojené státy, 14263
- Roswell Park Cancer Institute
-
Lake Success, New York, Spojené státy, 11042
- Northwell Health/Center for Advanced Medicine
-
New York, New York, Spojené státy, 10019
- Mount Sinai West
-
New York, New York, Spojené státy, 10029
- Mount Sinai Hospital
-
New York, New York, Spojené státy, 10011
- Mount Sinai Chelsea
-
New York, New York, Spojené státy, 10075
- Lenox Hill Hospital
-
New York, New York, Spojené státy, 10065
- Manhattan Eye Ear and Throat Hospital
-
Oswego, New York, Spojené státy, 13126
- Upstate Cancer Center at Oswego
-
Oswego, New York, Spojené státy, 13126
- Upstate Cancer Center Radiation Oncology at Oswego
-
Syracuse, New York, Spojené státy, 13210
- State University of New York Upstate Medical University
-
Syracuse, New York, Spojené státy, 13215
- SUNY Upstate Medical Center-Community Campus
-
Syracuse, New York, Spojené státy, 13210
- Upstate Cancer Center at Hill Radiation Oncology
-
Verona, New York, Spojené státy, 13478
- Upstate Cancer Center at Verona
-
-
North Carolina
-
Durham, North Carolina, Spojené státy, 27710
- Duke University Medical Center
-
Raleigh, North Carolina, Spojené státy, 27609
- Duke Cancer Center Raleigh
-
Winston-Salem, North Carolina, Spojené státy, 27157
- Wake Forest University Health Sciences
-
-
Ohio
-
Akron, Ohio, Spojené státy, 44304
- Summa Health System - Akron Campus
-
-
Oklahoma
-
Lawton, Oklahoma, Spojené státy, 73505
- Cancer Centers of Southwest Oklahoma Research
-
Oklahoma City, Oklahoma, Spojené státy, 73104
- University of Oklahoma Health Sciences Center
-
Oklahoma City, Oklahoma, Spojené státy, 73120
- Mercy Hospital Oklahoma City
-
-
Oregon
-
Gresham, Oregon, Spojené státy, 97030
- Legacy Mount Hood Medical Center
-
Portland, Oregon, Spojené státy, 97239
- Oregon Health and Science University
-
Portland, Oregon, Spojené státy, 97210
- Legacy Good Samaritan Hospital and Medical Center
-
Tualatin, Oregon, Spojené státy, 97062
- Legacy Meridian Park Hospital
-
-
Pennsylvania
-
Chadds Ford, Pennsylvania, Spojené státy, 19317
- Christiana Care Health System-Concord Health Center
-
Danville, Pennsylvania, Spojené státy, 17822
- Geisinger Medical Center
-
Hershey, Pennsylvania, Spojené státy, 17033-0850
- Penn State Milton S Hershey Medical Center
-
Lewisburg, Pennsylvania, Spojené státy, 17837
- Geisinger Medical Oncology-Lewisburg
-
Reading, Pennsylvania, Spojené státy, 19605
- Penn State Health Saint Joseph Medical Center
-
Wilkes-Barre, Pennsylvania, Spojené státy, 18711
- Geisinger Wyoming Valley/Henry Cancer Center
-
-
South Carolina
-
Charleston, South Carolina, Spojené státy, 29425
- Medical University of South Carolina
-
-
Texas
-
Amarillo, Texas, Spojené státy, 79106
- The Don and Sybil Harrington Cancer Center
-
-
Virginia
-
Richmond, Virginia, Spojené státy, 23235
- VCU Massey Cancer Center at Stony Point
-
Richmond, Virginia, Spojené státy, 23298
- VCU Massey Comprehensive Cancer Center
-
Tappahannock, Virginia, Spojené státy, 22560
- VCU Health Tappahannock Hospital
-
-
Washington
-
Vancouver, Washington, Spojené státy, 98686
- Legacy Salmon Creek Hospital
-
Vancouver, Washington, Spojené státy, 98684
- Legacy Cancer Institute Medical Oncology and Day Treatment
-
Walla Walla, Washington, Spojené státy, 99362
- Providence Saint Mary Regional Cancer Center
-
-
West Virginia
-
Charleston, West Virginia, Spojené státy, 25304
- Vandalia Health/CAMC Institute for Academic Medicine
-
-
Wisconsin
-
Ashland, Wisconsin, Spojené státy, 54806
- Northwest Wisconsin Cancer Center
-
Eau Claire, Wisconsin, Spojené státy, 54701
- Marshfield Medical Center-EC Cancer Center
-
La Crosse, Wisconsin, Spojené státy, 54601
- Gundersen Lutheran Medical Center
-
La Crosse, Wisconsin, Spojené státy, 54601
- Mayo Clinic Health System-Franciscan Healthcare
-
Marshfield, Wisconsin, Spojené státy, 54449
- Marshfield Medical Center-Marshfield
-
Minocqua, Wisconsin, Spojené státy, 54548
- Marshfield Medical Center - Minocqua
-
Mukwonago, Wisconsin, Spojené státy, 53149
- ProHealth D N Greenwald Center
-
New Richmond, Wisconsin, Spojené státy, 54017
- Cancer Center of Western Wisconsin
-
Oconomowoc, Wisconsin, Spojené státy, 53066
- ProHealth Oconomowoc Memorial Hospital
-
Rice Lake, Wisconsin, Spojené státy, 54868
- Marshfield Medical Center-Rice Lake
-
Stevens Point, Wisconsin, Spojené státy, 54482
- Marshfield Medical Center-River Region at Stevens Point
-
Waukesha, Wisconsin, Spojené státy, 53188
- UW Cancer Center at ProHealth Care
-
Weston, Wisconsin, Spojené státy, 54476
- Marshfield Medical Center - Weston
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Histologic or cytologic diagnosis of stage IV NSCLC using version American Joint Committee on Cancer (AJCC) 8th edition (includes M1a, M1b, and M1c stage disease). Patients with stage IIIB and IIIC disease are eligible if they are not a candidate for combined chemotherapy and radiation
- PD-L1 expression tumor proportion score (TPS) < 1% in tumor cells. If PD-L1 expression TPS is unevaluable or the testing could not be completed patients are not eligible. The assay must have been performed locally by a Clinical Laboratory Improvement Act (CLIA) (or equivalent) certified laboratory. The type of assay will be recorded
- For non-squamous patients only (adenocarcinoma or adenosquamous): EGFR, ALK and ROS1 testing must be done locally. No patients with known actionable EGFR mutations (except exon 20 insertion), ALK or ROS1 mutations that can be treated with oral tyrosine inhibitors
- Measurable disease based on RECIST 1.1, including at least two cancerous deposits. At least one deposit must be RECIST measurable (and not to be irradiated) while at least one OTHER deposit (measurable or non-measurable) must meet criteria for three 8 gray (Gy) doses of radiation
- Age >= 18 years
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- No more than three weeks of treatment with systemic chemotherapy or immunotherapy for advanced NSCLC
- No more than three weeks of treatment with checkpoint inhibitors for metastatic lung cancer
- No treatment with chemotherapy or immunotherapy for non-metastatic disease (e.g., adjuvant therapy) within 6 months prior to registration
- No systemic immunostimulatory or immunosuppressive drugs, including > 10 mg prednisone equivalent per day, within 2 weeks or 5 half-live of the drug, whichever is shorter. Steroid premedication per local standard is allowed
- >= 1 week prior to registration since palliative (including central nervous system [CNS]) radiotherapy to any tumor site
- No prior allogeneic tissue/solid organ transplant
- No uncontrolled intercurrent illness including, but not limited to, serious ongoing or active infection, symptomatic congestive heart failure, uncontrolled cardiac arrhythmia, unstable angina pectoris, that would limit compliance with study requirements
- No current pneumonitis or history of non-infectious pneumonitis that required steroids
- Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of registration
- No active auto-immune disease that requires systemic therapy within 2 years prior to registration. Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid release therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed
- No known history of hepatitis B (defined as hepatitis B surface antigen [HBsAg] reactive) or known hepatitis C virus (defined as HCV ribonucleic acid [RNA] [qualitative] is detected) infection
- No patients with symptomatic central nervous system metastases and/or carcinomatous meningitis. Patients with small asymptomatic brain metastases are eligible as are patients with treated brain metastases that require no steroids
- Not pregnant and not nursing, because this study involves radiation as well as potentially chemotherapy which have known genotoxic, mutagenic and teratogenic effects. Therefore, for women of childbearing potential only, a negative urine or serum pregnancy test done =< 7 days prior to registration is required
- No patients with a "currently active" second malignancy that is progressing or has required active treatment within the last 2 years. Participants with non-melanoma skin cancers or carcinoma in-situ (e.g., breast carcinoma, urothelial carcinoma or cervical cancer in situ) or localized prostate cancer (T1-3, N0, M0) that have undergone potentially curative therapy are eligible
- No hypersensitivity (>= grade 3) to immunotherapy and/or any of its excipients
- No live vaccine within 30 days prior to registration. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guerin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g.,FluMist [registered trademark]) are live attenuated vaccines and are not allowed. COVID-19 vaccine is allowed
- Absolute neutrophil count (ANC) >= 1,500/mm^3
- Platelet count >= 100,000/mm^3
- Calculated (Calc.) creatinine clearance >= 45 mL/min
- Total bilirubin =< 1.5 x upper limit of normal (ULN)
- Aspartate aminotransferase (AST) / alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Arm A (immunotherapy, +/- chemotherapy)
Patients receive nivolumab intravenously (IV) over 30 minutes on days 1 and 22 and ipilimumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 6 weeks for 24 months in the absence of disease progression or unacceptable toxicity or patients may receive standard of care systemic immunotherapy. Patients also undergo MRI, CT, or PET throughout the trial. Patients may undergo blood sample collection and tissue biopsy on study as well as ECHO during screening. |
Ancillary studies
Ostatní jména:
Undergo blood sample collection
Ostatní jména:
Given IV
Ostatní jména:
Undergo CT
Ostatní jména:
Undergo MRI
Ostatní jména:
Undergo ECHO
Ostatní jména:
Undergo PET
Ostatní jména:
Given IV
Ostatní jména:
Undergo tissue biopsy
Ostatní jména:
|
|
Experimentální: Arm B (immunotherapy, +/- chemotherapy, radiation therapy)
Patients receive 1 of 6 treatment options as in Arm A. Patients also undergo 3 fractions of radiation therapy every other day. Patients also undergo MRI, CT, or PET throughout the trial. Patients may undergo blood sample collection and tissue biopsy on study as well as ECHO during screening. |
Ancillary studies
Ostatní jména:
Undergo blood sample collection
Ostatní jména:
Given IV
Ostatní jména:
Undergo CT
Ostatní jména:
Undergo MRI
Ostatní jména:
Undergo ECHO
Ostatní jména:
Undergo PET
Ostatní jména:
Given IV
Ostatní jména:
Undergo radiation therapy
Ostatní jména:
Undergo tissue biopsy
Ostatní jména:
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Progression-free survival (PFS) (Phase II)
Časové okno: From randomization to disease progression or death of all causes, whichever comes first, assessed up to 5 years
|
Will be performed on an intent-to-treat (ITT) basis. |
From randomization to disease progression or death of all causes, whichever comes first, assessed up to 5 years
|
|
Overall survival (OS) (Phase III)
Časové okno: From randomization and death of all causes, assessed up to 5 years
|
Will be performed on an ITT basis. The comparison of the distributions of OS between treatment arms will be done with a one-sided stratified log-rank test). The rates at various time points (e.g., every 6 months after randomization) and medians of OS for each arm will be estimated using the Kaplan-Meier estimator. The associated 95% confidence interval (CI) will be calculated using Greenwood's formula and based on a log-log transformation applied on the survival function. Hazard ratios will be estimated using a stratified Cox regression model. The final phase III analysis of OS will be considered as "positive" if the stratified log-rank test statistics Z-value greater than the critical value adjusted for type 1 error using group sequential methods. Multivariable Cox models will be used to evaluate the treatment effect on survival time and its interaction with baseline covariates, including stage, systemic therapy, histology and performance status. |
From randomization and death of all causes, assessed up to 5 years
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Kvalita života
Časové okno: Až 5 let
|
Až 5 let
|
|
|
PFS
Časové okno: From randomization to disease progression or death of all causes, whichever comes first, assessed up to 5 years
|
Assessed per Response Evaluation Criteria in Solid Tumors (RECIST). |
From randomization to disease progression or death of all causes, whichever comes first, assessed up to 5 years
|
|
Objective response rate (ORR)
Časové okno: Up to 5 years
|
Assessed per RECIST for both irradiated and un-irradiated areas. The ORRs between treatments will be compared with Fisher's exact test. The difference of ORR between treatments will be estimated by the Miettinen-Nurminen method and its 95% CI will be given. Multivariable logistic regression will be used to evaluate the treatment effect on ORR while adjusting for significant baseline covariates. |
Up to 5 years
|
|
Incidence of treatment-related adverse events
Časové okno: Up to 5 years
|
Treatment-related toxicity will be summarized by grade, type, and system organ class. Comparisons of the percentages of patients experiencing an adverse event between Arm A and Arm B will be performed using Fisher's exact test. |
Up to 5 years
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Vrchní vyšetřovatel: Christine M Bestvina, Alliance for Clinical Trials in Oncology
Publikace a užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
- Novotvary podle místa
- Novotvary
- Nemoci dýchacích cest
- Novotvary podle histologického typu
- Plicní onemocnění
- Novotvary, žlázové a epiteliální
- Adenokarcinom
- Novotvary dýchacího traktu
- Novotvary hrudníku
- Karcinom
- Karcinom, Bronchogenní
- Bronchiální novotvary
- Adenokarcinom plic
- Novotvary plic
- Karcinom, nemalobuněčné plíce
- Aminokyseliny, peptidy a proteiny
- Proteiny
- Vyšetřovací techniky
- Terapeutika
- Klinické laboratorní techniky
- Diagnostické techniky a postupy
- Diagnóza
- Chirurgické postupy, operativní
- Cytologické techniky
- Cytodiagnosis
- Biologické faktory
- Fyzické jevy
- Protilátky, monoklonální, humanizované
- Protilátky, monoklonální
- Protilátky
- Imunoglobuliny
- Imunoproteiny
- Krevní proteiny
- Sérové globuliny
- Globuliny
- Diagnostické techniky, chirurgické
- Techniky chemie, analytické
- Analýza spektra
- Receptory, buněčný povrch
- Membránové proteiny
- Antigeny
- Antigeny, povrch
- Biomarkery
- Receptory, imunologické
- Antigeny, diferenciace, t-lymfocyt
- Antigeny, diferenciace
- Proteiny imunitního kontrolního bodu
- Kostimulační a inhibiční receptory T-buněk
- Nivolumab
- Ipilimumab
- Radioterapie
- Záření
- Biopsie
- Manipulace se vzorkem
- Magnetická rezonanční spektroskopie
- Antigen CTLA-4
Další identifikační čísla studie
- NCI-2021-06042
- U10CA180821 (Grant/smlouva NIH USA)
- NCI-2021-06042 (Identifikátor registru: CTRP (Clinical Trial Reporting Program))
- A082002 (Jiný identifikátor: CTEP)
- A082002 (Jiný identifikátor: Alliance for Clinical Trials in Oncology)
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
produkt vyrobený a vyvážený z USA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .